Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)

NCT03018405 is registered in ClinicalTrials.gov with Celyad Oncology SA as lead sponsor.

NCT NCT03018405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03018405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
Lead sponsor
Celyad Oncology SA
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2016
Completion date
August 31, 2021
Enrollment
146 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia/myelodysplastic syndrome, multiple myeloma (mm)